GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zhejiang East-Asia Pharmaceutical Co Ltd (SHSE:605177) » Definitions » EV-to-EBITDA

Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) EV-to-EBITDA : 19.98 (As of Sep. 25, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Zhejiang East-Asia Pharmaceutical Co EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Zhejiang East-Asia Pharmaceutical Co's enterprise value is ¥2,299 Mil. Zhejiang East-Asia Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was ¥115 Mil. Therefore, Zhejiang East-Asia Pharmaceutical Co's EV-to-EBITDA for today is 19.98.

The historical rank and industry rank for Zhejiang East-Asia Pharmaceutical Co's EV-to-EBITDA or its related term are showing as below:

SHSE:605177' s EV-to-EBITDA Range Over the Past 10 Years
Min: 15.37   Med: 24.16   Max: 38.31
Current: 19.66

During the past 8 years, the highest EV-to-EBITDA of Zhejiang East-Asia Pharmaceutical Co was 38.31. The lowest was 15.37. And the median was 24.16.

SHSE:605177's EV-to-EBITDA is ranked worse than
72.73% of 462 companies
in the Biotechnology industry
Industry Median: 8.71 vs SHSE:605177: 19.66

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-09-25), Zhejiang East-Asia Pharmaceutical Co's stock price is ¥17.15. Zhejiang East-Asia Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was ¥0.710. Therefore, Zhejiang East-Asia Pharmaceutical Co's PE Ratio for today is 24.15.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Zhejiang East-Asia Pharmaceutical Co EV-to-EBITDA Historical Data

The historical data trend for Zhejiang East-Asia Pharmaceutical Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang East-Asia Pharmaceutical Co EV-to-EBITDA Chart

Zhejiang East-Asia Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial - 15.75 17.27 8.88 11.98

Zhejiang East-Asia Pharmaceutical Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.56 20.59 11.98 17.56 25.03

Competitive Comparison of Zhejiang East-Asia Pharmaceutical Co's EV-to-EBITDA

For the Biotechnology subindustry, Zhejiang East-Asia Pharmaceutical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhejiang East-Asia Pharmaceutical Co's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zhejiang East-Asia Pharmaceutical Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Zhejiang East-Asia Pharmaceutical Co's EV-to-EBITDA falls into.



Zhejiang East-Asia Pharmaceutical Co EV-to-EBITDA Calculation

Zhejiang East-Asia Pharmaceutical Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=2299.455/115.098
=19.98

Zhejiang East-Asia Pharmaceutical Co's current Enterprise Value is ¥2,299 Mil.
Zhejiang East-Asia Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥115 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zhejiang East-Asia Pharmaceutical Co  (SHSE:605177) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Zhejiang East-Asia Pharmaceutical Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=17.15/0.710
=24.15

Zhejiang East-Asia Pharmaceutical Co's share price for today is ¥17.15.
Zhejiang East-Asia Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.710.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Zhejiang East-Asia Pharmaceutical Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Zhejiang East-Asia Pharmaceutical Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhejiang East-Asia Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
Laodong North Road, 23rd Floor, General Chamber of Commerce Building, Huangyan District, Zhejiang Province, Taizhou, CHN
Zhejiang East-Asia Pharmaceutical Co Ltd is mainly engaged in the production of bulk pharmaceutical chemicals, tablets, granules and capsules. The company's main products are: Ofloxacin, levofloxacin, loratadine hydrochloride, levofloxacin hydrochloride, trimebutine maleate, ketoconazole, terbinafine hydrochloride, piperazine, ticlazole and so on.

Zhejiang East-Asia Pharmaceutical Co Headlines

No Headlines